Statins, Cholesterol and Cognitive Decline in Alzheimer's
- Registration Number
- NCT06635252
- Lead Sponsor
- Karolinska Institutet
- Brief Summary
Disturbances in brain cholesterol homeostasis may be involved in the pathogenesis of Alzheimer's disease (AD). Lipid-lowering medications could interfere with neurodegenerative processes in AD through cholesterol metabolism or other mechanisms. The investigators aim to estimate the causal effect of statins on cognitive function measured by MMSE and to identify the mediating or modifying effect of cholesterol between statins and cognitive function in patients with Alzheimer's disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2000
All patients with AD and mixed dementia registered in SveDem and from SCREAM.
- All patients with a missing MMSE score at diagnosis date will be excluded from the analyses.
- Patients with at least one measurement of low-density lipoprotein cholesterol (LDL-C) within 1 year before dementia diagnosis.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients with Alzheimer's disease STA 4783 Prospective cohort study based on data from the Stockholm Creatinine Measurements (SCREAM) project. Patients diagnosed with AD and mixed dementia and registered in the Swedish Registry for Cognitive/Dementia Diseases are included.
- Primary Outcome Measures
Name Time Method Cognitive decline Through study completion, at least 1 year The data on cognitive change will be assessed by Mini Mental State Examination (MMSE) score. The MMSE score ranges from 0 and 30. Higher scores mean a better outcome.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Karolinska Institutet
🇸🇪Stockholm, Sweden